Article
COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine.
Pharmacogenomics - 1 Jan 2015
Bosia Marta, Lorenzi Cristina, Pirovano Adele, Guglielmino Carmelo, Cocchi Federica, Spangaro Marco, Bramanti Placido, Smeraldi Enrico, Cavallaro Roberto
Abstract excerpt
AIM: Clozapine is still considered the gold standard for treatment-resistant schizophrenia patients; however, up to 40% of patients do not respond adequately. Identifying potential predictors of clinical response to this last-line antipsychotic could represent an important goal for treatment. Among these, functional polymorphisms involved in dopamine system modulation, known to be disrupted in schizophrenia, may...
Topics
Join the communities discussing this publication.
